Clinical Trial Update: Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC

View source ↗

Summary

This clinical trial update notes an eribulin mesylate–based therapy being studied for advanced HER2-negative breast cancer previously treated with antibody-drug…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Halaven (eribulin mesylate) (eribulin mesylate)

Snippet

Sponsor: Fudan University | Conditions: Treatment Efficacy | Status: NOT_YET_RECRUITING